La asociacion entre Lp(a) y el riesgo cardiovascular fueron atenuadas y no significativas entre los individuos con niveles más bajos de IL-6 atherosclerosis-journal.com/… También la inflamación modula la Lp(a) @ATHjournal

☝️Atherosclerosis & Dementia: The Missing Link? 👉A new review reinforces a concept lipidologists and preventive cardiologists should not ignore: what damages arteries may also damage the brain. 1️⃣ Up to 45% of dementia cases may be preventable through modification of cardiovascular risk factors. 2️⃣ High LDL-C, elevated triglycerides, hypertension, type 2 diabetes, obesity, and smoking show the strongest evidence as causal risk factors for late-life dementia. 3️⃣ Genetic and Mendelian randomization studies increasingly support a role for apoB-containing lipoproteins in dementia risk, strengthening the vascular-brain connection. 4️⃣ Emerging evidence suggests that lipid-lowering therapies, particularly statins, may reduce dementia risk beyond cardiovascular protection. 5️⃣ The take-home message is simple: early prevention matters. By the time dementia becomes clinically apparent, decades of vascular and neurodegenerative injury may already have occurred. 🧠🤝❤️ What is good for the heart is good for the brain. ☝️Perhaps the strongest argument yet for aggressive lifetime management of LDL-C and overall cardiometabolic risk. 🔓🔗 atherosclerosis-journal.com/… @society_eas @ATHjournal @nationallipid

✅Lipoproteínas remanente ✅Inflamación O ambas ➡️➡️Donde esta el aumento de riesgo?⬅️⬅️ atherosclerosis-journal.com/… Vía @ATHjournal

Concordance of Lipoprotein(a) measurements in mg/dL and nmol/L: Insights from the Lp(a)HORIZON trial atherosclerosis-journal.com/… Vía @ATHjournal

Or if you don’t like suspense, you can also read our simultaneous publication in @ATHjournal here: doi.org/10.1016/j.atheroscle… @virani_md @CBallantyneMD @vijay_nambi @albertdansoosei

RT @LipidoSeen: Revisión marcadores de ➡️Marcadores circulantes y marcadores de imagen evaluados mediante técnicas ➡️invasivas y no invasiv…

Our latest publication is out! 🌍 500 lipid clinics across 55 countries. Proud to contribute to this new global EAS consensus about lipid clinics, alongside outstanding international colleagues. 🧬 Earlier diagnosis- Better LDL-C control @society_eas @ATHjournal @EASCongress

From vulnerable plaque to vulnerable patient. Isabel Gonçalves’ 🆕 @ATHjournal review asks whether imaging circulating markers can predict plaque vulnerability. Catch her #EASCongress2026 plenary: 🕘 09:14 | Anitschkow Hall 🔗 atherosclerosis-journal.com/… @EASCongress @society_eas

RT @LipidoSeen: La epidemiologia, genética respaldan que TRL-RC es un factor causal y modificable del riesgo de evento Debiéramos.priorizar…

A new era in atherothrombosis 🚀 Prof. Lina Badimon’s @ATHjournal review explores how lipids, inflammation and thrombosis are reshaping ASCVD care. More tomorrow at #EASCongress2026 🕣 08:30 | Anitschkow Hall 🔗 atherosclerosis-journal.com/… #MyEAS2026 @EASCongress @society_eas

RT @LipidoSeen: Los conocimientos sobre ✅progresión aterosclerosis ✅interacción factores de riesgo vascular y lpared vascular ✅disfunción e…

Remnant cholesterol: no longer just a biomarker?Following Prof. Rosenson’s #EASCongress2026 plenary, this @ATHjournal review makes the case for RC as a causal, modifiable contributor to residual ASCVD risk 🔗atherosclerosis-journal.com/… #MyEAS2026 @EASCongress @society_eas

RT @LipidoSeen: El ejercicio reduce la inflamación y ralentiza la acumulación de placa ✅Recupera lesion cardíaca después de IAM ✅Reduce el…

CHIP, loss of Y chrom, inflammation, ath: a lot to discuss❗️ In @ATHjournal, Ramos-Neble reviews hematopoietic somatic mutations in ASCVD. Perfect reading ahead of SaaG session on CAD genetics & clonal hematopoiesis at #EASCongress2026 🔗 atherosclerosis-journal.com/… #MyEAS2026

How do genetics and modifiable risk interact in ath❓ Prof. Heribert Schunkert addresses this in a 🆕 @ATHjournal review, and will discuss it tonight during the Anitschkow Lecture at #EASCongress2026. 🕡 18:45–19:30 📍 Anitschkow Hall 🔗 atherosclerosis-journal.com/… #MyEAS2026

Inflammation in ASCVD: measurable, targetable, clinically actionable 🌟 A timely #EASCongress2026 read in @ATHjournal, where Prof. Ridker revisits key lessons from his 2025 Anitschkow Lecture: hsCRP, residual inflammatory risk, CANTOS and IL-6 inhibition 🔗atherosclerosis-journal.com/…

👉Just published in Atherosclerosis — a true milestone for the global lipid community. 🌍🫀 ☝️The new EAS Consensus Statement on lipid clinics brings together experts from 55 countries and more than 500 lipid clinics to provide practical guidance on harmonization, organization, staffing, education, patient pathways, and funding of lipid services worldwide. 📌 Why it matters: • Establishes a global framework for lipid clinic development • Promotes equitable access to high-quality lipid care • Supports earlier diagnosis and better management of inherited and complex lipid disorders • Strengthens prevention of ASCVD on a worldwide scale • Highlights the importance of education, registries, and multidisciplinary care ☝️A fantastic initiative by the European Atherosclerosis Society Lipid Clinic Network and all contributing authors. Proud to have participated in this important international effort. ☝️A must-read for anyone involved in preventive cardiology, lipidology, cardiovascular prevention, and healthcare policy. 🔓🔗 atherosclerosis-journal.com/… @society_eas @ATHjournal @BNordestgaard @ProfKausikRay

What is good for the 🫀 may also be good for the 🧠 In @ATHjournal, Prof. Ruth Frikke-Schmidt reviews the links btw ath and dementia, w/ a focus on causality and prevention Catch her lecture 🔜 at #EASCongress2026 🕤 09:36–09:58 🔗 atherosclerosis-journal.com/… #MyEAS2026 @society_eas

What if one of the most powerful CV tools is also one of the simplest❓ In @ATHjournal, Prof. Hendrik B. Sager and colleagues review exercise as medicine for cardiovascular health. Catch his lecture 🔜 at #EASCongress2026 🕘 09:14–09:36 🔗 atherosclerosis-journal.com/… #MyEAS2026

#EASCongress2026 starts today, and some of the science will move from the stage to the page. During the @EASCongress, @ATHjournal will publish reviews by selected presenters on 🗝️ topics discussed in 🇬🇷. Keep an 👁️ on 👇 atherosclerosis-journal.com/… ... and spread the word! #MyEAS2026